Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T R Jones

Showing results (171-180 of 212) with videos related to

Pageof 22
Sort By:
Canadian Journal of Physiology and Pharmacology|February 1, 1995
Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonistT R Jones, M Labelle, M Belley, et al.
Canadian Journal of Physiology and Pharmacology|September 1, 1989
The pharmacology of L-670,596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonistA W Ford-Hutchinson, Y Girard, A Lord, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
L-648,051: an aerosol active leukotriene D4 receptor antagonistT R Jones, Y Guindon, E Champion, et al.
European Journal of Pharmacology|March 17, 1987
Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonistR A Hall, J Gillard, Y Guindon, et al.
Journal of Medicinal Chemistry|April 15, 1994
Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acidJ H Hutchinson, D Riendeau, C Brideau, et al.
Canadian Journal of Physiology and Pharmacology|December 1, 1991
Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571T R Jones, R Zamboni, M Belley, et al.
The American Journal of Tropical Medicine and Hygiene|December 1, 1993
Age-specific prevalence of Plasmodium falciparum among six populations with limited histories of exposure to endemic malariaJ K Baird, Purnomo, H Basri, et al.
Canadian Journal of Physiology and Pharmacology|January 1, 1989
Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonistT R Jones, R Zamboni, M Belley, et al.
Canadian Journal of Physiology and Pharmacology|August 1, 1986
L-649,923, sodium (beta S*, gamma R*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)- gamma-hydroxy-beta-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonistT R Jones, R Young, E Champion, et al.
The American Journal of Tropical Medicine and Hygiene|February 1, 1994
Malaria vaccine study site in Irian Jaya, Indonesia: Plasmodium falciparum incidence measurements and epidemiologic considerations in sample size estimationT R Jones, J K Baird, M J Bangs, et al.
Pageof 22

Showing results (171-180 of 212) with videos related to

Sort By:
Pageof 22
Canadian Journal of Physiology and Pharmacology|February 1, 1995
Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonistT R Jones, M Labelle, M Belley, et al.
Canadian Journal of Physiology and Pharmacology|September 1, 1989
The pharmacology of L-670,596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonistA W Ford-Hutchinson, Y Girard, A Lord, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
L-648,051: an aerosol active leukotriene D4 receptor antagonistT R Jones, Y Guindon, E Champion, et al.
European Journal of Pharmacology|March 17, 1987
Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonistR A Hall, J Gillard, Y Guindon, et al.
Journal of Medicinal Chemistry|April 15, 1994
Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acidJ H Hutchinson, D Riendeau, C Brideau, et al.
Canadian Journal of Physiology and Pharmacology|December 1, 1991
Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571T R Jones, R Zamboni, M Belley, et al.
The American Journal of Tropical Medicine and Hygiene|December 1, 1993
Age-specific prevalence of Plasmodium falciparum among six populations with limited histories of exposure to endemic malariaJ K Baird, Purnomo, H Basri, et al.
Canadian Journal of Physiology and Pharmacology|January 1, 1989
Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonistT R Jones, R Zamboni, M Belley, et al.
Canadian Journal of Physiology and Pharmacology|August 1, 1986
L-649,923, sodium (beta S*, gamma R*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)- gamma-hydroxy-beta-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonistT R Jones, R Young, E Champion, et al.
The American Journal of Tropical Medicine and Hygiene|February 1, 1994
Malaria vaccine study site in Irian Jaya, Indonesia: Plasmodium falciparum incidence measurements and epidemiologic considerations in sample size estimationT R Jones, J K Baird, M J Bangs, et al.
Pageof 22